SpinaFX Medical, a Canadian clinical-stage device company, has received FDA Investigational Device Exemption (IDE) approval for its Triojection system, enabling a pivotal U.S. trial for contained lumbar disc herniation. This milestone opens a potential new minimally invasive option for patients who fail conservative care, signaling a supply-chain opportunity for distributors and clinics eyeing non-surgical spine solutions.
Regulatory milestone
The U.S. Food and Drug Administration granted the IDE on June 9, 2026, allowing SpinaFX to initiate a prospective, randomized, multicenter trial. The study will enroll 300 patients across up to 30 U.S. sites, comparing intradiscal ozone/oxygen injection plus nerve root block against nerve root block alone in patients with contained herniated lumbar discs who have not responded to conservative therapy.
Clinical and market context
SpinaFX highlights a recognized "therapeutic gap" between failed conservative care and surgery for contained disc herniation. Published literature from outside the United States reports encouraging clinical findings for intradiscal ozone therapy, providing background support for the U.S. investigation. The company notes that the condition affects millions globally, representing a large addressable market with significant unmet need and high healthcare costs.
Trial design and endpoints
Primary and secondary endpoints will include clinically meaningful measures of pain and function at 6, 12, 18, and 24 months. Site and core laboratory partnerships are under discussion to ensure study execution and data quality. The trial is designed to generate evidence for a future FDA marketing authorization application.
What buyers should watch
For medical aesthetics distributors and clinic buyers, this development signals a potential new category in non-surgical spine care. If the trial succeeds, Triojection could become a reimbursable, minimally invasive option for patients who currently have limited choices between conservative care and surgery. SpinaFX has representation in nine offices worldwide, suggesting a global distribution network may be in development. Importers and clinic operators should monitor trial outcomes and FDA decisions, as successful clearance could create demand for ozone delivery systems and related consumables.
Sourcing context
SpinaFX Medical is headquartered in Toronto, Canada, and has previously received FDA Breakthrough Device Designation for Triojection in August 2025. The company acknowledges MCRA for regulatory assistance. The therapy remains investigational in the United States, and any regulatory, clinical, reimbursement, or commercial outcomes depend on trial results and subsequent FDA review.
Source: Read the original report | Published: June 09, 2026